Exelixis Inc
EXEL37.430USD
0.0000.00%
收盤 04/25, 16:00（美東）報價延遲15分鐘
10.55B總市值
20.23本益比TTM
關於 Exelixis Inc 公司
Exelixis, Inc. 是一家腫瘤學公司。該公司已生產了四種上市藥品，其中兩種是其旗艦分子卡博替尼的配方。該公司還在推進和發展其產品線組合，包括其主要研究資產 zanzalintinib。卡博替尼是多種酪氨酸激酶的抑制劑，包括 MET、AXL、VEGF 受體和 RET，還被批准作爲 CABOMETYX 片劑用於晚期腎細胞癌、先前治療過的肝細胞癌和先前治療過的放射性碘難治性分化性甲狀腺癌，以及作爲 COMETRIQ 膠囊用於進行性轉移性髓樣甲狀腺癌。該公司的另外兩種產品是 COTELLIC，一種 MEK 抑制劑，被批准作爲多種聯合方案的一部分用於治療特定形式的晚期黑色素瘤，以及 MINNEBRO，一種口服、非甾體、選擇性鹽皮質激素受體阻滯劑，在日本被批准用於治療高血壓。
公司簡介
公司代碼EXEL
公司名稱Exelixis Inc
上市日期Apr 11, 2000
成立日期1994
CEODr. Michael M. Morrissey, Ph.D.
員工數量1147
證券類型Ordinary Share
年結日Apr 11
公司地址1851 Harbor Bay Parkway
城市ALAMEDA
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94502
電話16508377000
網址https://www.exelixis.com/
公司代碼EXEL
上市日期Apr 11, 2000
成立日期1994
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.37M
+33.08%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.26M
+0.15%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
469.73K
+48.81%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
391.52K
+51.34%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
347.62K
+75.36%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
337.77K
+2.73%
Dr. Amy C. Peterson, M.D.
Dr. Amy C. Peterson, M.D.
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
192.16K
+486.28%
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Independent Director
Independent Director
150.18K
+1.27%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
72.17K
+2.67%
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
763.00
-92.92%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.37M
+33.08%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.26M
+0.15%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
469.73K
+48.81%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
391.52K
+51.34%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
347.62K
+75.36%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
337.77K
+2.73%
收入明細
單位: USD更新時間: 4月6日 週日
單位: USD更新時間: 4月6日 週日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
CABOMETYX
1.80B
82.92%
License revenues
349.24M
16.10%
COMETRIQ
11.16M
0.51%
Collaboration services revenues
10.06M
0.46%
地區USD
名稱
營收
佔比
U.S
1.82B
84.06%
Europe
318.63M
14.69%
Japan
27.08M
1.25%
業務
地區
業務USD
名稱
營收
佔比
CABOMETYX
1.80B
82.92%
License revenues
349.24M
16.10%
COMETRIQ
11.16M
0.51%
Collaboration services revenues
10.06M
0.46%
股東統計
更新時間: 2月21日 週五
更新時間: 2月21日 週五
持股股東
股東類型
持股股東
股東統計
佔比
The Vanguard Group, Inc.
10.66%
BlackRock Institutional Trust Company, N.A.
9.69%
Farallon Capital Management, L.L.C.
8.51%
Renaissance Technologies LLC
5.55%
State Street Global Advisors (US)
4.14%
Other
61.45%
持股股東
股東統計
佔比
The Vanguard Group, Inc.
10.66%
BlackRock Institutional Trust Company, N.A.
9.69%
Farallon Capital Management, L.L.C.
8.51%
Renaissance Technologies LLC
5.55%
State Street Global Advisors (US)
4.14%
Other
61.45%
股東類型
股東統計
佔比
Investment Advisor/Hedge Fund
35.97%
Investment Advisor
33.06%
Hedge Fund
18.79%
Pension Fund
2.95%
Individual Investor
2.28%
Research Firm
1.77%
Sovereign Wealth Fund
1.22%
Bank and Trust
0.48%
Family Office
0.10%
Other
3.38%
機構持股
更新時間: 1月20日 週一
更新時間: 1月20日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
972
265.48M
94.85%
-6.82M
2024Q4
992
262.76M
93.66%
-11.36M
2024Q3
924
259.58M
90.96%
-10.18M
2024Q2
908
255.61M
87.75%
-22.29M
2024Q1
905
264.69M
87.26%
-20.82M
2023Q4
882
270.85M
87.07%
-16.64M
2023Q3
847
278.02M
87.32%
-18.15M
2023Q2
833
285.95M
87.85%
-21.34M
2023Q1
841
294.75M
90.97%
-14.08M
2022Q4
839
295.50M
91.62%
-5.46M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
29.37M
10.49%
+120.47K
+0.41%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
26.71M
9.54%
-308.83K
-1.14%
Dec 31, 2024
Farallon Capital Management, L.L.C.
23.44M
8.37%
--
--
Mar 05, 2025
Renaissance Technologies LLC
15.30M
5.47%
-64.05K
-0.42%
Dec 31, 2024
State Street Global Advisors (US)
11.41M
4.08%
-31.73K
-0.28%
Dec 31, 2024
LSV Asset Management
8.17M
2.92%
+67.47K
+0.83%
Dec 31, 2024
Fuller & Thaler Asset Management Inc.
7.63M
2.73%
+708.31K
+10.23%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.16M
1.84%
-5.12K
-0.10%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
5.10M
1.82%
-153.57K
-2.92%
Dec 31, 2024
AQR Capital Management, LLC
3.97M
1.42%
+810.86K
+25.69%
Dec 31, 2024
查看更多
持股ETF
更新時間: 4月6日 週日
更新時間: 4月6日 週日
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
4.81%
Tema Oncology ETF
4.2%
Alger Russell Innovation ETF
3.77%
First Trust NYSE Arca Biotechnology Index Fund
3.34%
Burney US Factor Rotation ETF
3.31%
Invesco Biotechnology & Genome ETF
2.89%
ERShares Entrepreneurs ETF
2.66%
First Trust Health Care Alphadex Fund
2.51%
Range Cancer Immunotherapy ETF
2.48%
Adaptiv Select ETF
2.04%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比4.81%
Tema Oncology ETF
佔比4.2%
Alger Russell Innovation ETF
佔比3.77%
First Trust NYSE Arca Biotechnology Index Fund
佔比3.34%
Burney US Factor Rotation ETF
佔比3.31%
Invesco Biotechnology & Genome ETF
佔比2.89%
ERShares Entrepreneurs ETF
佔比2.66%
First Trust Health Care Alphadex Fund
佔比2.51%
Range Cancer Immunotherapy ETF
佔比2.48%
Adaptiv Select ETF
佔比2.04%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據